Fiche publication


Date publication

janvier 2015

Journal

Journal of market access & health policy

Auteurs

Résumé

The use of pharmacokinetics is associated with cost savings in anti-tumor necrosis factor (anti-TNF) therapy, but the long-term cost savings in a large cohort of Crohn's disease (CD) patients are unknown.

Mots clés

Crohn's disease, adalimumab, cost saving, infliximab, pharmacokinetics

Référence

J Mark Access Health Policy. 2015 ;3: